MAOA’s role in cellular changes and therapy resistance in prostate cancer
Official title: Delineating the Impact of MAOA on Cellular Plasticity and Heterogeneity in Therapy Resistant Prostate Cancer
Funded at Washington State University · NIH-11368131 · Data updated 2026-11-12
This grant explores how MAOA contributes to cellular flexibility and heterogeneous behavior in advanced prostate cancer that no longer responds to standard anti-androgen therapies.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Washington State University NIH-funded |
| Lab location | 1 site (Pullman, United States) |
| Project start | January 1, 2019 |
| Project end | June 30, 2031 |
| Funding year | 2026 |
| Award (this year) | $447,400 |
| NIH project number | 2R01CA233658-08A1 |
| Project ID | NIH-11368131 on NIH RePORTER |
Who could benefit from this research
✓Could help
Patients with advanced, treatment-resistant prostate cancer, particularly those with tumors showing lineage plasticity or altered AR signaling, may benefit from future therapies arising from this work.
✕Less likely to help
Patients with early-stage or non-AR-driven cancers not targeted by anti-androgen strategies may see no direct benefit.
What this research studies
Prostate cancer can become aggressive and resistant to therapies that target androgen signaling. This project studies how MAOA affects the ability of cancer cells to change their identity and behavior, which may drive treatment resistance. Researchers will use human cancer cells to understand plasticity, identify druggable targets, and test strategies to prevent or overcome resistance. The work aims to inform treatments that keep anti-androgen therapies effective longer for patients.
Why it matters
Potential benefit: If successful, the research could lead to new ways to prevent or delay resistance to anti-androgen therapies in prostate cancer.
How similar studies have gone: Previous studies have linked MAOA to aggressive features in prostate cancer, supporting potential benefit from targeting this pathway, though translational results are still emerging.
Where this research is happening
-
Washington State University
Pullman, United States Active
Researchers
- Principal investigator: Wu, Boyang — Washington State University
- Study coordinator: Wu, Boyang
Related research
Other NIH-funded projects on the same topics.
-
Cardiovascular risk planning and reduction for men with prostate cancer
A program to better predict and reduce heart disease risk in men treated for prostate cancer, especially older patients.
-
Effects of ADT on motivation and emotion in prostate cancer patients
This project looks at how androgen deprivation therapy may affect motivation and mood over time in men with prostate cancer.
-
Causal Protein Markers to Understand and Predict Prostate Cancer Risk in Africans and Europeans
A cancer research project looking at proteins linked to prostate cancer to better understand why it happens and how risk differs between African and European populations.
-
Ethical multimodal AI platform to improve prostate cancer detection with ultrasound
A patient-friendly AI system uses ultrasound and MRI information to help doctors better find prostate cancer, aiming to improve accuracy and access.
-
Characterizing epigenetic targets in prostate cancer to help AR-driven cancer
A research project at MD Anderson aims to understand how epigenetic factors shape androgen receptor signaling in prostate cancer to find new ways to treat resistant forms of the disease.
-
AR and RNA-binding in prostate cancer resistance
A cancer research grant exploring how the androgen receptor’s interaction with RNA may drive treatment resistance in prostate cancer, with potential to guide new therapies.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.